Fig. 3: In vivo efficacy in the NHP challenge model.
a, Overview of study design for the SARS-CoV-2 NHP challenge model. Animals MF1 and MF2 were intravenously administered 10 mg kg−1 of P2G3 and challenged 3 d later (day 0) along with control animals MF3 and MF4 via intranasal and intratracheal inoculation of the Omicron BA.1 SARS-CoV-2 virus (1 × 105 TCID50). b,c, Tracheal swabs (left), nasopharyngeal swabs (middle) and bronchoalveolar lavages (BAL, right) performed during the course of the study were evaluated for viral copies per ml of gRNA (b) and sgRNA (c), with data plotted to include two historical control animals (MF5* and MF6*) infected with the same inoculum of Omicron virus. d, Flow cytometry analysis of blood samples from NHPs collected throughout the study shows strong lymphopenia in control animals following challenge with Omicron SARS-CoV-2, while P2G3 LS-treated monkeys show stable levels of lymphocytes. Dotted line indicates lower limit of detection at 2.68- and 2.87-log copies per ml for viral gRNA and sgRNA, respectively.
